North America Non-Radiographic Axial Spondyloarthritis Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.1.1 THREAT OF NEW ENTRANTS

4.1.2 THREAT OF SUBSTITUTES

4.1.3 BARGAINING POWER OF BUYERS

4.1.4 BARGAINING POWER OF SUPPLIERS

4.1.5 INDUSTRY RIVALRY

4.2 BRAND OUTLOOK

4.3 COST ANALYSIS BREAKDOWN

4.3.1 DRUG ACQUISITION COSTS AND PRICING DYNAMICS

4.3.2 MANUFACTURING AND BIOLOGICS PRODUCTION COSTS

4.3.3 RESEARCH AND DEVELOPMENT EXPENDITURE

4.3.4 DISTRIBUTION, LOGISTICS, AND COLD CHAIN MANAGEMENT

4.3.5 ADMINISTRATION AND HEALTHCARE SYSTEM COSTS

4.3.6 IMPACT OF BIOSIMILARS AND COMPETITIVE PRICING

4.3.7 REIMBURSEMENT FRAMEWORKS AND PATIENT ACCESS

4.3.8 MARKET DEVELOPMENTS INFLUENCING COST STRUCTURES

4.3.9 CONCLUSION

4.4 INDUSTRY ECOSYSTEM ANALYSIS

4.4.1 OVERVIEW OF THE INDUSTRY ECOSYSTEM STRUCTURE

4.4.2 DRUG DISCOVERY AND TRANSLATIONAL RESEARCH ECOSYSTEM

4.4.3 CLINICAL DEVELOPMENT AND TRIAL INFRASTRUCTURE

4.4.4 MANUFACTURING AND BIOPHARMACEUTICAL SUPPLY CHAIN ECOSYSTEM

4.4.5 REGULATORY AND HEALTH AUTHORITY ECOSYSTEM

4.4.6 HEALTHCARE DELIVERY AND PRESCRIBING ECOSYSTEM

4.4.7 DISTRIBUTION AND PHARMACEUTICAL ACCESS CHANNELS

4.4.8 PATIENT ADVOCACY AND DISEASE AWARENESS ECOSYSTEM

4.4.9 PRICING AND MARKET ACCESS ECOSYSTEM

4.5 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.5.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

4.5.1.1 JOINT VENTURES

4.5.1.2 MERGERS AND ACQUISITIONS

4.5.1.3 LICENSING AND PARTNERSHIP

4.5.1.4 TECHNOLOGY COLLABORATIONS

4.5.1.5 STRATEGIC DIVESTMENTS

4.5.2 NUMBER OF PRODUCTS IN DEVELOPMENT

4.5.3 STAGE OF DEVELOPMENT

4.5.4 TIMELINES AND MILESTONES

4.5.5 INNOVATION STRATEGIES AND METHODOLOGIES

4.5.6 RISK ASSESSMENT AND MITIGATION

4.5.7 FUTURE OUTLOOK

4.6 PATENT ANALYSIS

4.6.1 PATENT QUALITY AND STRENGTH

4.6.2 COUNTRY PATENT LANDSCAPE.

4.6.3 IP STRATEGY AND MANAGEMENT

4.6.4 LICENSING AND COLLABORATION

4.7 PRICING ANALYSIS

4.7.1 PREMIUM PRICING STRUCTURE DOMINATED BY BIOLOGICS AND TARGETED THERAPIES

4.7.2 BIOLOGICS AS THE KEY REVENUE AND PRICE REALIZATION SEGMENT

4.7.3 LOW-COST VOLUME SEGMENT LED BY NSAIDS AND CONVENTIONAL THERAPIES

4.7.4 REGIONAL PRICING DISPARITY ACROSS NORTH AMERICA MARKETS

4.7.5 BIOSIMILARS DRIVING DOWNWARD PRICE CORRECTION

4.7.6 HEALTH ECONOMIC BURDEN AND PAYER-DRIVEN PRICING PRESSURE

4.8 PROFIT MARGINS SCENARIO

4.8.1 OVERVIEW OF PROFIT MARGIN DYNAMICS

4.8.2 REVENUE STRUCTURE AND PRICING POWER IN BIOLOGIC THERAPIES

4.8.3 COST STRUCTURE AND MANUFACTURING ECONOMICS

4.8.4 IMPACT OF BIOSIMILARS AND COMPETITIVE EROSION

4.8.5 REGIONAL REIMBURSEMENT AND MARKET ACCESS INFLUENCE

4.8.6 PIPELINE INNOVATION AND MARGIN EXPANSION POTENTIAL

4.8.7 REGULATORY APPROVALS AND MARKET EXPANSION CONTEXT

4.8.8 COMPETITIVE AND CLINICAL ADOPTION DYNAMICS

4.8.9 INNOVATION-DRIVEN MARGIN SUSTAINABILITY

4.8.10 CONCLUSION

4.9 RAW MATERIAL COVERAGE

4.9.1 OVERVIEW OF RAW MATERIAL LANDSCAPE

4.9.2 BIOLOGIC ACTIVE INGREDIENT PRODUCTION INPUTS

4.9.3 CELL CULTURE MEDIA AND UPSTREAM PROCESSING MATERIALS

4.9.4 CHROMATOGRAPHY AND PURIFICATION MATERIALS

4.9.5 FORMULATION EXCIPIENTS AND STABILIZATION AGENTS

4.9.6 PRIMARY PACKAGING MATERIALS

4.9.7 SECONDARY PACKAGING AND COLD CHAIN LOGISTICS MATERIALS

4.9.8 QUALITY STANDARDS AND REGULATORY MATERIAL COMPLIANCE

4.9.9 SUPPLY CHAIN CONSTRAINTS AND RISK FACTORS

4.9.10 EMERGING TRENDS IN RAW MATERIAL INNOVATION

4.1 TECHNOLOGICAL ADVANCEMENTS

4.10.1 EVOLUTION OF TARGETED BIOLOGIC THERAPIES

4.10.2 EMERGENCE OF IL-17 INHIBITORS AND NOVEL MECHANISTIC PATHWAYS

4.10.3 ADVANCEMENT OF ORAL SMALL MOLECULE THERAPIES

4.10.4 BIOMARKER-DRIVEN DIAGNOSIS AND TREATMENT OPTIMIZATION

4.10.5 DIGITAL HEALTH INTEGRATION AND REMOTE MONITORING

4.10.6 ADVANCES IN DRUG DELIVERY SYSTEMS

4.10.7 ONGOING RESEARCH IN NEXT-GENERATION THERAPEUTICS

4.10.8 INTEGRATION OF PRECISION MEDICINE APPROACHES

4.10.9 CONCLUSION

4.11 VALUE CHAIN ANALYSIS

4.11.1 RAW MATERIALS AND ACTIVE PHARMACEUTICAL INGREDIENTS

4.11.2 DRUG DISCOVERY AND PRECLINICAL DEVELOPMENT

4.11.3 MANUFACTURING AND BIOPROCESSING

4.11.4 PROCESSING, FILL-FINISH AND STERILIZATION

4.11.5 PACKAGING AND LABELING

4.11.6 DISTRIBUTION AND LOGISTICS

4.11.7 CONCLUSION

4.12 VENDOR SELECTION CRITERIA

4.12.1 CLINICAL EFFICACY AND EVIDENCE-BASED DIFFERENTIATION

4.12.2 MECHANISM OF ACTION AND PORTFOLIO BREADTH

4.12.3 REGULATORY COMPLIANCE AND NORTH AMERICA MARKET ACCESS

4.12.4 PRICING STRATEGY AND REIMBURSEMENT LANDSCAPE

4.12.5 MANUFACTURING CAPABILITIES AND SUPPLY CHAIN RELIABILITY

4.12.6 STRATEGIC COLLABORATIONS AND INNOVATION CAPACITY

4.12.7 REAL-WORLD EVIDENCE AND POST-MARKETING SURVEILLANCE

4.12.8 MARKET PRESENCE AND PHYSICIAN ENGAGEMENT

4.12.9 CONCLUSION

5 TARIFFS & IMPACT ON THE MARKET

5.1 CURRENT TARIFF RATE(S) IN TOP-5 COUNTRY MARKETS

5.2 OUTLOOK: LOCAL PRODUCTION VERSUS IMPORT RELIANCE

5.3 VENDOR SELECTION CRITERIA DYNAMICS

5.4 IMPACT ON SUPPLY CHAIN

5.4.1 RAW MATERIAL PROCUREMENT

5.4.2 MANUFACTURING AND PRODUCTION

5.4.3 LOGISTICS AND DISTRIBUTION

5.4.4 PRICE PITCHING AND MARKET POSITION

5.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES

5.5.1 SUPPLY CHAIN OPTIMIZATION

5.5.2 JOINT VENTURE ESTABLISHMENTS

6 REGULATORY FRAMEWORK AND APPROVAL PATHWAYS

6.1 OVERVIEW

6.2 REGIONAL REGULATORY AND REIMBURSEMENT LANDSCAPES

6.3 PRICING, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE

6.4 POST-MARKETING SURVEILLANCE AND PHARMACOVIGILANCE

7 MARKET OVERVIEW

7.1 DRIVER

7.1.1 INCREASING PREVALENCE OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND IMPROVED DISEASE AWARENESS

7.1.2 GROWING ADOPTION OF BIOLOGICS SUCH AS TNF INHIBITORS AND IL-17 INHIBITORS FOR EARLY-STAGE TREATMENT

7.1.3 ADVANCEMENTS IN DIAGNOSTIC TECHNIQUES ENABLING EARLIER AND MORE ACCURATE DETECTION

7.1.4 RISING HEALTHCARE EXPENDITURE AND IMPROVED ACCESS TO SPECIALTY CARE IN EMERGING MARKETS

7.2 RESTRAINT

7.2.1 HIGH COST OF BIOLOGIC THERAPIES LIMITING PATIENT ACCESS IN LOW- AND MIDDLE-INCOME REGIONS

7.2.2 STRINGENT REGULATORY APPROVAL PROCESSES FOR NOVEL THERAPEUTICS DELAYING MARKET ENTRY

7.3 OPPORTUNITIES

7.3.1 DEVELOPMENT OF TARGETED THERAPIES AND NOVEL BIOLOGICS WITH IMPROVED EFFICACY AND SAFETY PROFILES

7.3.2 EXPANSION OF BIOSIMILARS MARKET REDUCING TREATMENT COSTS AND IMPROVING ACCESSIBILITY

7.3.3 GROWING FOCUS ON PERSONALIZED MEDICINE AND PRECISION THERAPEUTICS

7.4 CHALLENGES

7.4.1 COMPLEXITY IN DISEASE DIAGNOSIS DUE TO LACK OF RADIOGRAPHIC EVIDENCE IN EARLY STAGES

7.4.2 PATIENT ADHERENCE ISSUES DUE TO CHRONIC NATURE OF TREATMENT

8 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.2.1 NORTH AMERICA

8.2.2 EUROPE

8.2.3 ASIA-PACIFIC

8.2.4 SOUTH AMERICA

8.2.5 MIDDLE EAST & AFRICA

8.3 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

8.3.1 MEDICATION

8.3.2 SURGERY

8.3.3 PHYSICAL THERAPY

8.3.4 OTHERS

8.4 NORTH AMERICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.4.1 BIOLOGICS

8.4.2 NSAIDS

8.4.3 ANALGESICS

8.4.4 DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)

8.4.5 OTHERS

8.5 NORTH AMERICA BIOLOGICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.5.1 TNF INHIBITORS

8.5.2 INTERLEUKIN (IL-17) INHIBITORS

8.5.3 JAK INHIBITORS

8.5.4 OTHERS

8.6 NORTH AMERICA TNF INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.6.1 ADALIMUMAB

8.6.2 ETANERCEPT

8.6.3 CERTOLIZUMAB PEGOL

8.6.4 INFLIXIMAB

8.6.5 OTHERS

8.7 NORTH AMERICA INTERLEUKIN (IL-17) INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.7.1 SECUKINUMAB

8.7.2 IXEKIZUMAB

8.7.3 OTHERS

8.8 NORTH AMERICA JAK INHIBITORS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.8.1 UPADACITINIB

8.8.2 TOFACITINIB

8.8.3 OTHERS

8.9 NORTH AMERICA NSAIDS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.9.1 TRADITIONAL NSAIDS

8.9.2 SELECTIVE COX-2 INHIBITORS

8.9.3 OTHERS

8.1 NORTH AMERICA MEDICATION IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.10.1 NORTH AMERICA

8.10.2 EUROPE

8.10.3 ASIA-PACIFIC

8.10.4 SOUTH AMERICA

8.10.5 MIDDLE EAST AND AFRICA

8.11 NORTH AMERICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.11.1 JOINT REPLACEMENT

8.11.2 SPINAL FUSION

8.11.3 OTHERS

8.12 NORTH AMERICA SURGERY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.12.1 NORTH AMERICA

8.12.2 EUROPE

8.12.3 ASIA-PACIFIC

8.12.4 SOUTH AMERICA

8.12.5 MIDDLE EAST AND AFRICA

8.13 NORTH AMERICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.13.1 EXERCISE-BASED APPROACHES

8.13.2 HYDROTHERAPY

8.13.3 OTHERS

8.14 NORTH AMERICA PHYSICAL THERAPY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.14.1 NORTH AMERICA

8.14.2 EUROPE

8.14.3 ASIA-PACIFIC

8.14.4 SOUTH AMERICA

8.14.5 MIDDLE EAST AND AFRICA

8.15 NORTH AMERICA OTHER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.15.1 NORTH AMERICA

8.15.2 EUROPE

8.15.3 ASIA-PACIFIC

8.15.4 SOUTH AMERICA

8.15.5 MIDDLE EAST AND AFRICA

9 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG

9.1 OVERVIEW

9.2 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

9.2.1 ADALIMUMAB

9.2.2 SECUKINUMAB

9.2.3 ETANERCEPT

9.2.4 IXEKIZUMAB

9.2.5 UPADACITINIB

9.2.6 CERTOLIZUMAB PEGOL

9.2.7 GOLIMUMAB

9.2.8 INFLIXIMAB

9.2.9 TOFACITINIB

9.2.10 OTHERS

9.3 NORTH AMERICA ADALIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.3.1 NORTH AMERICA

9.3.2 EUROPE

9.3.3 ASIA-PACIFIC

9.3.4 SOUTH AMERICA

9.3.5 MIDDLE EAST AND AFRICA

9.4 NORTH AMERICA SECUKINUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.4.1 NORTH AMERICA

9.4.2 EUROPE

9.4.3 ASIA-PACIFIC

9.4.4 SOUTH AMERICA

9.4.5 MIDDLE EAST AND AFRICA

9.5 NORTH AMERICA ETANERCEPT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.5.1 NORTH AMERICA

9.5.2 EUROPE

9.5.3 ASIA-PACIFIC

9.5.4 SOUTH AMERICA

9.5.5 MIDDLE EAST AND AFRICA

9.6 NORTH AMERICA IXEKIZUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.6.1 NORTH AMERICA

9.6.2 EUROPE

9.6.3 ASIA-PACIFIC

9.6.4 SOUTH AMERICA

9.6.5 MIDDLE EAST AND AFRICA

9.7 NORTH AMERICA UPADACITINIB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.7.1 NORTH AMERICA

9.7.2 EUROPE

9.7.3 ASIA-PACIFIC

9.7.4 SOUTH AMERICA

9.7.5 MIDDLE EAST AND AFRICA

9.8 NORTH AMERICA CERTOLIZUMAB PEGOL IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.8.1 NORTH AMERICA

9.8.2 EUROPE

9.8.3 ASIA-PACIFIC

9.8.4 SOUTH AMERICA

9.8.5 MIDDLE EAST AND AFRICA

9.9 NORTH AMERICA GOLIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.9.1 NORTH AMERICA

9.9.2 EUROPE

9.9.3 ASIA-PACIFIC

9.9.4 SOUTH AMERICA

9.9.5 MIDDLE EAST AND AFRICA

9.1 NORTH AMERICA INFLIXIMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.10.1 NORTH AMERICA

9.10.2 EUROPE

9.10.3 ASIA-PACIFIC

9.10.4 SOUTH AMERICA

9.10.5 MIDDLE EAST AND AFRICA

9.11 NORTH AMERICA TOFACITINIB IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.11.1 NORTH AMERICA

9.11.2 EUROPE

9.11.3 ASIA-PACIFIC

9.11.4 SOUTH AMERICA

9.11.5 MIDDLE EAST AND AFRICA

9.12 NORTH AMERICA OTHER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.12.1 NORTH AMERICA

9.12.2 EUROPE

9.12.3 ASIA-PACIFIC

9.12.4 SOUTH AMERICA

9.12.5 MIDDLE EAST AND AFRICA

10 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

10.2.1 SUBCUTANEOUS

10.2.2 ORAL

10.2.3 INTRAVENOUS

10.2.4 OTHERS

10.3 NORTH AMERICA SUBCUTANEOUS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.3.1 NORTH AMERICA

10.3.2 EUROPE

10.3.3 ASIA-PACIFIC

10.3.4 SOUTH AMERICA

10.3.5 MIDDLE EAST AND AFRICA

10.4 NORTH AMERICA ORAL IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPE

10.4.3 ASIA-PACIFIC

10.4.4 SOUTH AMERICA

10.4.5 MIDDLE EAST AND AFRICA

10.5 NORTH AMERICA INTRAVENOUS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.5.1 NORTH AMERICA

10.5.2 EUROPE

10.5.3 ASIA-PACIFIC

10.5.4 SOUTH AMERICA

10.5.5 MIDDLE EAST AND AFRICA

10.6 NORTH AMERICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPE

10.6.3 ASIA-PACIFIC

10.6.4 SOUTH AMERICA

10.6.5 MIDDLE EAST AND AFRICA

11 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER

11.1 OVERVIEW

11.2 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY END USER, 2018-2033 (USD THOUSAND)

11.2.1 SPECIALTY CLINICS

11.2.2 HOMECARE

11.2.3 HOSPITALS

11.2.4 PHARMACY & RETAILERS

11.2.5 OTHERS

11.3 NORTH AMERICA SPECIALTY CLINICS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPE

11.3.3 ASIA-PACIFIC

11.3.4 SOUTH AMERICA

11.3.5 MIDDLE EAST AND AFRICA

11.4 NORTH AMERICA HOMECARE IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.4.1 NORTH AMERICA

11.4.2 EUROPE

11.4.3 ASIA-PACIFIC

11.4.4 SOUTH AMERICA

11.4.5 MIDDLE EAST AND AFRICA

11.5 NORTH AMERICA HOSPITALS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.5.1 NORTH AMERICA

11.5.2 EUROPE

11.5.3 ASIA-PACIFIC

11.5.4 SOUTH AMERICA

11.5.5 MIDDLE EAST AND AFRICA

11.6 NORTH AMERICA PHARMACY & RETAILERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.6.1 NORTH AMERICA

11.6.2 EUROPE

11.6.3 ASIA-PACIFIC

11.6.4 SOUTH AMERICA

11.6.5 MIDDLE EAST AND AFRICA

11.7 NORTH AMERICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.7.1 NORTH AMERICA

11.7.2 EUROPE

11.7.3 ASIA-PACIFIC

11.7.4 SOUTH AMERICA

11.7.5 MIDDLE EAST AND AFRICA

12 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

12.2.1 HOSPITAL PHARMACY

12.2.2 RETAIL PHARMACY

12.2.3 DIRECT TENDER

12.2.4 ONLINE PHARMACY

12.2.5 OTHERS

12.3 NORTH AMERICA HOSPITAL PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.3.1 NORTH AMERICA

12.3.2 EUROPE

12.3.3 ASIA-PACIFIC

12.3.4 SOUTH AMERICA

12.3.5 MIDDLE EAST AND AFRICA

12.4 NORTH AMERICA RETAIL PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.4.1 NORTH AMERICA

12.4.2 EUROPE

12.4.3 ASIA-PACIFIC

12.4.4 SOUTH AMERICA

12.4.5 MIDDLE EAST AND AFRICA

12.5 NORTH AMERICA DIRECT TENDER IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.5.1 NORTH AMERICA

12.5.2 EUROPE

12.5.3 ASIA-PACIFIC

12.5.4 SOUTH AMERICA

12.5.5 MIDDLE EAST AND AFRICA

12.6 NORTH AMERICA ONLINE PHARMACY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.6.1 NORTH AMERICA

12.6.2 EUROPE

12.6.3 ASIA-PACIFIC

12.6.4 SOUTH AMERICA

12.6.5 MIDDLE EAST AND AFRICA

12.7 NORTH AMERICA OTHERS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.7.1 NORTH AMERICA

12.7.2 EUROPE

12.7.3 ASIA-PACIFIC

12.7.4 SOUTH AMERICA

12.7.5 MIDDLE EAST AND AFRICA

13 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET, BY REGION

13.1 NORTH AMERICA

13.1.1 U.S.

13.1.2 CANADA

13.1.3 MEXICO

14 NORTH AMERICA NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THERAPEUTICS MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILE MANUFRACTURER

16.1 NOVARTIS AG

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 PFIZER INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 ABBVIE INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 UCB S.A.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 LILLY

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 BIOGEN

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 ALKEM

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 AMGEN INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 ASTELLAS PHARMA INC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 BIOCAD

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

16.12 BRISTOL-MYERS SQUIBB (BMS)

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CELLTRION INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENTS

16.14 CIPLA

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 DR.REDDY’S LABORATORIES LTD.

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 F. HOFFMANN-LA ROCHE LTD

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 FRESENIUS SE & CO. KGAA

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.18 GEDEON RICHTER PLC.

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENTS

16.19 JOHNSON & JOHNSON AND ITS AFFILIATES

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 KYOWA KIRIN CO., LTD.

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 LUPIN

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENTS

16.22 MERCK KGAA

16.22.1 COMPANY SNAPSHOT

16.22.2 REVENUE ANALYSIS

16.22.3 PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 SAMSUNG BIOEPIS

16.23.1 COMPANY SNAPSHOT

16.23.2 PRODUCT PORTFOLIO

16.23.3 RECENT DEVELOPMENT

16.24 SANDOZ.INC

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PRODUCT PORTFOLIO

16.24.4 RECENT DEVELOPMENT

16.25 SANOFI

16.25.1 COMPANY SNAPSHOT

16.25.2 REVENUE ANALYSIS

16.25.3 PRODUCT PORTFOLIO

16.25.4 RECENT DEVELOPMENT

16.26 SUN PHARMACEUTICAL INDUSTRIES LTD.

16.26.1 COMPANY SNAPSHOT

16.26.2 REVENUE ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENTS

16.27 TAKEDA PHARMACEUTICAL COMPANY LIMITED.

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 TEVA PHARMACEUTICAL INDUSTRIES LTD.

16.28.1 COMPANY SNAPSHOT

16.28.2 REVENUE ANALYSIS

16.28.3 PRODUCT PORTFOLIO

16.28.4 RECENT DEVELOPMENT

16.29 TORRENT PHARMACEUTICALS LTD.

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PRODUCT PORTFOLIO

16.29.4 RECENT DEVELOPMENTS

16.3 VIATRIS INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 REVENUE ANALYSIS

16.30.3 PRODUCT PORTFOLIO

16.30.4 RECENT DEVELOPMENTS

16.31 ZYDUS GROUP

16.31.1 COMPANY SNAPSHOT

16.31.2 REVENUE ANALYSIS

16.31.3 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT

17 COMPANY PROFILE DISTRIBUTOR

17.1 ALFRESA PHARMA CORPORATION

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 ASTUTE HEALTHCARE LTD.

17.2.1 COMPANY SNAPSHOT

17.2.2 PRODUCT PORTFOLIO

17.2.3 RECENT DEVELOPMENT

17.3 CARDINAL HEALTH

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.4 CENCORA, INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 MCKESSON CORPORATION

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 MEDIPAL HOLDINGS CORPORATION

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 PHOENIX PHARMA SE

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENT

17.8 SMITH DRUG COMPANY

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 ZUELLIG PHARMA

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS